Gilead gets green light for remdesivir use for Covid-19 in Japan
The drugmaker got the nod just three days after making the application with Japan citing ‘exceptional circumstances’ for the rapid approval
07 May 2020 - 18:42
Tokyo— Japan approved the antiviral drug remdesivir for use against the novel coronavirus on Thursday, three days after receiving an application from Gilead Sciences, the company said in a statement.
The rapid move by Japan’s usually conservative authorities comes days after the US authorised the drug for emergency use on Covid-19 patients. The special approval process used in Japan is reserved for urgent situations, where there is no alternative, and the drug has already been authorised for use overseas...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.